Literature DB >> 36262899

Recurrence of Thrombotic Thrombocytopenic Purpura After Vaccination with mRNA-1273 COVID-19 vaccine.

Spyridon Ntelis1, Kathryn Champ1.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare disease characterized by thrombocytopenia, microangiopathic hemolytic anemia, and ischemic organ damage. Several cases of TTP associated with administration of COVID-19 vaccines have been reported. We report a case of a 63-year-old woman with a past medical history of hypertension, diabetes mellitus, chronic kidney disease, HIV infection, and remote history of TTP who presented with several days of shortness of breath on exertion, chest tightness, low-grade fever, and bruising thirty-three days after receiving the second dose of the mRNA-1273 COVID-19 vaccine. Thrombocytopenia and hemolytic anemia with schistocytes were noted on testing, and ADAMTS13 activity was <5%. Temporizing treatment with fresh frozen plasma was started immediately on presentation, and treatment was continued with daily therapeutic plasma exchange and corticosteroids. TTP should be considered in patients who present with thrombocytopenia after COVID-19 vaccination, especially if there is a past history of TTP.
© 2022 Greater Baltimore Medical Center.

Entities:  

Keywords:  COVID-19; Thrombotic thrombocytopenic purpura; mRNA-1273 vaccine

Year:  2022        PMID: 36262899      PMCID: PMC9533810          DOI: 10.55729/2000-9666.1073

Source DB:  PubMed          Journal:  J Community Hosp Intern Med Perspect        ISSN: 2000-9666


  20 in total

Review 1.  Thrombotic thrombocytopenic purpura.

Authors:  Shebli Atrash; Haider Sajjad; Ramos Jeanette; Arnaoutakis Konstantinos
Journal:  J Ark Med Soc       Date:  2015-02

Review 2.  Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease?

Authors:  Monte S Willis; Nicholas Bandarenko
Journal:  Semin Thromb Hemost       Date:  2005-12       Impact factor: 4.180

3.  ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

4.  First report of COVID-19 vaccine induced flare of compensated congenital thrombotic thrombocytopenic purpura.

Authors:  Kaitlyn C Dykes; Craig M Kessler
Journal:  Blood Coagul Fibrinolysis       Date:  2022-01-01       Impact factor: 1.276

5.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Authors:  Pedro M Folegatti; Katie J Ewer; Parvinder K Aley; Brian Angus; Stephan Becker; Sandra Belij-Rammerstorfer; Duncan Bellamy; Sagida Bibi; Mustapha Bittaye; Elizabeth A Clutterbuck; Christina Dold; Saul N Faust; Adam Finn; Amy L Flaxman; Bassam Hallis; Paul Heath; Daniel Jenkin; Rajeka Lazarus; Rebecca Makinson; Angela M Minassian; Katrina M Pollock; Maheshi Ramasamy; Hannah Robinson; Matthew Snape; Richard Tarrant; Merryn Voysey; Catherine Green; Alexander D Douglas; Adrian V S Hill; Teresa Lambe; Sarah C Gilbert; Andrew J Pollard
Journal:  Lancet       Date:  2020-07-20       Impact factor: 79.321

6.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Authors:  Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks
Journal:  N Engl J Med       Date:  2020-12-30       Impact factor: 91.245

7.  Relapse of thrombotic thrombocytopenic purpura after COVID-19 vaccine.

Authors:  Cinzia Sissa; Ahmad Al-Khaffaf; Francesco Frattini; Roberta Gaiardoni; Elda Mimiola; Paolo Montorsi; Barbara Melara; Massimo Amato; Flora Peyvandi; Massimo Franchini
Journal:  Transfus Apher Sci       Date:  2021-04-16       Impact factor: 1.764

Review 8.  Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine.

Authors:  Syed Hamza Bin Waqar; Anosh Aslam Khan; Shehzeen Memon
Journal:  Int J Hematol       Date:  2021-07-15       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.